Niagen BiosciencevsNewmont

NAGE and NEM stock compared: price, dividend, valuation and results, from SEC filings.

Niagen Bioscience (NAGE) has a market value of $155M and Newmont (NEM) $114B. Over the last year, with dividends, NAGE moved -72.0% and NEM +21.2%. The P/E is 15.2 for NAGE and 12.3 for NEM. Dividend yield: NAGE none, NEM 0.99%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    NAGE$155M

    NEM$114B

    NEM is 732 times NAGE

  • Revenue, 12 months

    NAGE$122M

    NEM$26.6B

    NEM is 218 times NAGE

  • Net income, 12 months

    NAGE$10M

    NEM$9.2B

    NEM is 902 times NAGE

  • Operating margin

    NAGE3.9%

    NEM–

  • ROIC

    NAGE5.6%

    NEM22.0%

    16.4 points apart

  • P/E

    NAGE15.2

    NEM12.3

    NAGE is 1.2 times NEM

  • Dividend yield

    NAGE0.0%

    NEM1.0%

    1.0 points apart

  • 5-year return

    NAGE-66.4%

    NEM+106.8%

    173.2 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

NAGE-66.4%

NEM+106.8%

10020020222023202420252026
Returns by period
PeriodNAGEWith dividendsNEMWith dividends
1 year since November 17, 2025-72.0%Price -72.0%+21.2%Price +20.0%
3 years since November 17, 2023+35.7%+10.7% a yearPrice +35.7%+204.6%+45.0% a yearPrice +187.6%
5 years since November 17, 2021-66.4%-19.6% a yearPrice -66.4%+106.8%+15.6% a yearPrice +80.4%
10 years since November 18, 2016-23.6%-2.7% a yearPrice -23.6%+309.1%+15.1% a yearPrice +219.8%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

NAGENiagen BioscienceNEMNewmont

Valuation

NAGENEM
Valuation
Price$1.94$104.53
Market value$155M$114B
Enterprise value (EV)$86M$110B
P/E15.212.3
P/E, 5-year median–15.6
P/B1.93.2
EV/EBIT18.07.8
Free cash flow yield–8.9%

Results and growth

NAGENEM
Results and growth
Revenue, 12 months$122M$26.6B
Net income, 12 months$10M$9.2B
Free cash flow, 12 months–$10.1B
Earnings per share, 12 months$0.12$8.60
Revenue growth, year on year30.0%21.3%
Revenue growth a year, past+16.9%over 5 years+14.5%over 5 years
EPS growth a year, past–+12.7%over 5 years

Margins and returns on capital

NAGENEM
Margins and returns on capital
Gross margin63.9%69.2%
Operating margin3.9%–
Net margin8.4%34.7%
ROIC5.6%22.0%
ROE13.0%26.7%

Balance sheet

NAGENEM
Balance sheet
Cash$70M$8.8B
Total debt$2.1M$5.1B
Net debt / EBITDA-12.9-0.2
Interest cover––

Dividends and buybacks

NAGENEM
Dividends and buybacks
Dividend yield–1.0%
Dividend per share, 12 months–$1.03
Dividend growth a year, past––
Buyback yield0.2%2.0%
Shareholder yield0.2%3.0%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: NAGE or NEM

Didn't find what you were looking for?

Ask us
Which is bigger, Niagen Bioscience or Newmont?

By market value, Newmont ($114B) is about 732.0 times Niagen Bioscience ($155M), at today's prices.

How did NAGE and NEM stock do over the last 10 years?

Since November 18, 2016, NAGE's price moved -23.6% and NEM's +219.8%. With dividends: NAGE -23.6% (-2.7% a year), NEM +309.1% (+15.1% a year). Past returns do not predict future ones.

Which pays the higher dividend, NAGE or NEM?

The dividend yield at today's price is none for Niagen Bioscience and 0.99% for Newmont. Over the last twelve months they paid – and $1.03 per share.

What is the P/E of NAGE and NEM?

At today's price, the P/E is 15.2 for NAGE and 12.3 for NEM. It is the share price over the last twelve months' earnings per share.

Which has the higher profit margins, Niagen Bioscience or Newmont?

Over the last twelve months, the net margin was 8.4% for Niagen Bioscience and 34.7% for Newmont, and the operating margin 3.9% and –. Revenue was $122M and $26.6B.

Which is the better investment, Niagen Bioscience or Newmont?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.